Lilly, Novo Fight Weight Loss Drug Compounders Over Shortage

Eli Lilly & Co. and Novo Nordisk A/S are asking a federal court to reject legal protections to drug compounders making copycat versions of the weight loss drug tirzepatide.

The two drugmakers moved Tuesday in the legal battle between the Food and Drug Administration and drug compounders over whether the the FDA lawfully determined that Lilly’s tirzepatide—a diabetes and obesity treatment branded as Mounjaro and Zepbound—is no longer in short supply in the US.

The Outsourcing Facilities Association and FarmaKeio Custom Compounding filed in January a motion for preliminary injunction in the US District Court for the Northern District of ...